PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 15, 2015--
Pharmaceuticals, Inc. (NASDAQ: PCRX) announced today that Aratana
Therapeutics, Inc. (NASDAQ: PETX) shared positive results from its
pivotal field effectiveness study of AT-003, the company’s bupivacaine
liposome injectable suspension licensed from Pacira, for managing
postsurgical pain in dogs.
The randomized, blinded, multicenter pivotal study in dogs undergoing
knee surgery demonstrated statistically significant improvements in pain
evaluation compared to placebo at each of the 24-hour intervals up to 72
hours following surgery (P<0.05). Based on current timelines for
the FDA approval process, Aratana anticipates beginning
commercialization of AT-003 in dogs in 2016.
In December 2012, Pacira and Aratana entered into a global licensing
agreement for the development and commercialization of bupivacaine
liposome injectable suspension for animal health indications.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is a specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company’s flagship product,
EXPAREL® (bupivacaine liposome injectable suspension), indicated for
single-dose infiltration into the surgical site to produce postsurgical
analgesia, was commercially launched in the United States in April 2012.
EXPAREL and two other products have successfully utilized DepoFoam®, a
unique and proprietary product delivery technology that encapsulates
drugs without altering their molecular structure, and releases them over
a desired period of time. Additional information about Pacira is
available at www.pacira.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150715005434/en/
Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
Susan Heins, 864-286-9597